FAP and cancer: As an additional means of testing ADC efficacy, we conducted cell killing assays using cellular reductive capacity as a readout for metabolic activity and cell viability, recapitulating the same dose-dependent and selective killing of FAP-expressing CWR-R1FAP but not CWR-R1 cancer cells (Supplemental Fig. 7).